Co-Development Partnerships
Accelerate Innovation Through
Co-Development
Join forces with SpeeDx to enhance your therapeutic and biotech solutions
If you have a focus on therapeutics, vaccines, or create products using living systems, our co-development partnerships provide new ways for you to more efficiently advance. Bypass years of in-house development and investment by accessing world-class multiplexing diagnostics technology from SpeeDx today. By combining your aptitude with our patented technologies, we can create solutions specific to your needs, from breakthrough personalised diagnostics to treatment efficacy testing, or research and development tools.
Our proven track record includes successful collaborations with GSK on novel AMR diagnostics, Sanofi on clinical trial monitoring, and Biocartis on complementary diagnostics and liquid biopsy testing for oncology. These partnerships demonstrate our ability to deliver clinical and commercial-ready solutions that meet rigorous performance and regulatory standards.
Whether you're a pharmaceutical or diagnostics company seeking to develop companion or complementary diagnostics for clinical implementation, for efficacy monitoring of drug or vaccine candidates during development, or a biotech needing new R&D tools to refine your research activities—SpeeDx provides the technical expertise, regulatory experience, and manufacturing infrastructure to accelerate your ambitions.
Joint Development Programs combine resources and expertise for breakthrough innovations with collaborative R&D, and shared regulatory strategies.
Companion/Complementary Diagnostic partnerships align diagnostics with therapeutic options, ultimately enabling clinician to stratify patients and define treatment pathways, and/or allow biotech companies to conduct post-market surveillance.
Efficacy Testing to monitor effectiveness of therapeutics and vaccines and help with today’s medical problems, e.g. monitoring patients with cancer or infectious diseases.
Clinical Trials or Research Tools to accelerate and refine R&D processes, allow precision monitoring of candidate therapies or vaccines during development, ultimately providing confidence in outcomes and reassurance in your final product.
With 15+ years of molecular multiplexing innovation and 100+ patents, SpeeDx can tailor solutions to your needs. From initial assay design through regulatory approval and commercial manufacturing, we've successfully delivered solutions for partners globally across every stage of the development journey.
Leaders in PCR Multiplexing
SpeeDx technology has been used for molecular diagnostics across 100+ laboratories in 30+ countries. Our ResistancePlus® and PlexPCR® assays process hundreds of thousands of samples annually, while providing cost-effective solutions for laboratories.
Proven at Scale
The SpeeDx R&D and Innovations development teams are highly knowledgeable and skilled assay developers. These experts love the challenge of a new project and apply a rigorous, hands-on approach to find the best solution to meet your needs.
Experienced Developers
Where competitors have lengthy timelines for multiplex assay development, our proprietary PlexPrime® and PlexZyme® technologies enable streamlined development cycles from concept through to validated assays. Along with our scale-up manufacturing expertise, we have your needs covered.
Rapid Development Timelines
Our team has navigated compliance across global regulatory frameworks for multiple product lines. We deliver technical validation packages under our ISO-13485 compliant frameworks for seamless integration into your regulatory dossiers.
Regulatory Expertise You Can Trust
Whether you need custom diagnostics or research assays, tests developed for your preferred instrumentation, or co-development of novel assays, we structure partnerships around your strategic objectives and commercial timelines.
Flexible Partnership Models
Why Partner with SpeeDx?
Benefit from the powerful PCR technologies and product development expertise at SpeeDx and enjoy a consultative approach to assay design. Each partnership model is unique—tailored to your strategic goals, risk tolerance, and commercialization plans—creating mutual value and long-term competitive advantages.
Unlike traditional vendor relationships, co-development partnerships create true strategic alignment through
shared investment, and shared commercialisation opportunities.
We structure partnerships to match your specific objectives.
"The game-changing real-time PCR based technology uses a unique combination of PlexZyme® and PlexPrime®, which allows very high sensitivity and specificity combined with high multiplexing capability."
Biocartis
How we partner with you
Joint Development Programme
Combine resources and expertise for breakthrough innovations:
-
Shared commercialization rights
-
Joint investment in development
-
Collaborative regulatory strategy
Companion/Complementary Diagnostics
Develop diagnostics aligned with therapeutic pipelines:
-
Patient stratification tools
-
Assays guiding treatment pathways
-
Surveillance solutions
Efficacy Testing
Uncover more when utilizing our novel multiplexing capabilities:
-
Monitor effectiveness of therapeutics and vaccines
-
Ensure rapid and reliable results
-
Comprehensive analysis packages
Clinical Trials and Research Tools
Standout from your competitors, lower costs and shorten timelines with refined R&D processes:
-
Precision monitoring
-
Improve quality of trials with robust testing solutions
-
Rapid, comprehensive and validated results
GSK Collaboration
Joint development of novel diagnostic solutions for global health challenges
Sanofi Partnership
Employing InSignia® to monitor antibiotic efficacy in clinical trials
Biocartis Oncology Menu
Incorporating PlexZyme® and PlexPrime® into complementary diagnostic and liquid biopsy tests
Partnering with Industry Leaders
Accelerate your diagnostic development
Whether you need to streamline development with access to over 100+ patents, work with a world leading technical team or navigate regulatory pathways to access global markets